Peptide PilotPeptide Pilot

Dose calculator

Tirzepatide dose calculator

Convert any Tirzepatide dose into syringe units in real time, pre-filled with a 10 mg / 2 mL example.

Download Peptide PilotiPhone · Free to download

Draw on a U-100 syringe

50.0 units

Volume to draw

0.500 mL

Tirzepatide is a once-a-week injection people use to lose weight and improve blood sugar control. It hits two gut-hormone receptors at once — GLP-1 and GIP — which is why it tends to drive larger appetite and weight changes than single-receptor drugs. In the SURMOUNT-1 trial, participants without diabetes lost roughly 20.9% of body weight over 72 weeks on the highest dose. This page covers reconstitution math and weekly dose logging.

How the Tirzepatide dose calculator works

This calculator answers a simple question: given the concentration of the Tirzepatide solution already in your vial, how many syringe units does today's dose work out to? It is the second half of the reconstitution math — the first half locks in concentration, this one converts any dose mg or mcg into a clean unit count.

The formula is volume in mL equals dose mg divided by concentration mg/mL, then volume times one hundred to get units on a U-100 insulin syringe. With a 5 mg/mL Tirzepatide solution and a 2.5 mg dose, the draw is 0.50 mL or about 50 units. Type any other dose and the unit count updates in real time — no spreadsheets, no guesswork.

Inputs that genuinely matter: concentration (which only changes when you reconstitute a new vial) and dose mass. Syringe type matters too, but only because U-100 vs U-40 changes the multiplier — almost every modern insulin syringe is U-100, which is why the math defaults to that. Edge cases worth flagging: switching from mcg to mg without checking the input unit, or carrying yesterday's unit count over to a new vial that was reconstituted with a different volume of BAC water.

Most people use this calculator at two moments: when titrating a dose up or down, and when prepping a single dose before injection. The output is meant to be checked against the syringe before drawing — read the markings, confirm the unit count, then draw. The calculator is fast precisely so you can do that check every time without it feeling like a chore.

How Tirzepatide dosing is tracked

Weekly subcutaneous injection is the default. Each draw is small enough that almost everyone uses a U-100 insulin syringe rather than a tuberculin syringe.

Tirzepatide protocols often involve gradual dose escalation over months, starting low and increasing every several weeks to reduce gastrointestinal side effects. Logging that escalation in real time — including the exact date and unit count of each step — is what makes the pattern auditable months later.

Vial-aware tracking is especially helpful for tirzepatide because the same vial can support many doses across a long stretch of weeks. Knowing exactly how many doses remain prevents the awkward case of opening a fresh vial and finding that the previous one still had several usable draws left.

Published research protocols for tirzepatide frequently describe a multi-step dose titration schedule that can span five months or longer. A widely studied pattern involves initiating at a 2.5 mg weekly dose and escalating monthly through subsequent tiers: 5 mg, 7.5 mg, 10 mg, 12.5 mg, and a final tier of 15 mg. For researchers documenting their work, this dose-stepping creates a significant planning challenge. To accurately observe such a protocol, one must schedule six discrete dosage levels over the course of the study, each requiring its own precise volume calculation prior to administration.

Tirzepatide mechanism in plain English

Tirzepatide binds to both the GIP and GLP-1 receptors. Activating both at once influences insulin secretion in response to glucose and produces effects on appetite and gastric emptying. The dual-agonist design is what produces the differentiated weight and metabolic responses tirzepatide is associated with relative to single-receptor GLP-1 agonists.

Researchers and individuals tracking tirzepatide typically pair the weekly dose with weight, hunger ratings, and side-effect notes. The interesting trends only become visible across many weeks of consistent logging — single data points rarely tell the story.

At a molecular level, tirzepatide is a single, unimolecular peptide designed to function as an agonist for two distinct receptors: the GLP-1 receptor and the GIP receptor. While it shares GLP-1 receptor activity with other peptides in its category, its concurrent activation of the GIP receptor introduces a separate insulinotropic action. The primary structural feature that distinguishes tirzepatide from a single agonist like semaglutide is its specific, biased ratio of binding affinity for the GIP receptor relative to the GLP-1 receptor. This engineered affinity balance is a core element of its molecular architecture and documented function.

Common Tirzepatide dose mistakes

  • Reusing the unit count from a previous vial after switching to a new vial that was reconstituted with a different diluent volume.
  • Skipping the escalation date in the log, then being unable to answer when a dose change actually happened.
  • Mixing up tirzepatide milligrams with semaglutide milligrams — the doses are typically much larger for tirzepatide and the math is not interchangeable.
  • Underestimating doses-per-vial on a high-strength vial because the vial looks small even though it contains many weeks of supply.
  • Letting reconstituted tirzepatide sit at room temperature on travel days when a small cooler bag would have kept it refrigerated.
  • Failing to recalculate the correct unit volume for each new dose during a multi-step titration schedule.
  • Attempting to draw a volume greater than 1 mL, such as 1.5 mL or 3 mL, into a standard 1-mL insulin syringe.
  • Mistaking the GIP-to-GLP-1 binding affinity ratio, a fixed molecular property, for a variable that can be adjusted during reconstitution or administration.

Frequently asked questions about Tirzepatide dose

How is tirzepatide reconstituted?
By drawing a measured volume of bacteriostatic water and injecting it slowly into the lyophilized vial through the rubber stopper, then swirling — not shaking — until the powder fully dissolves. Diluent volume choices typically range from 2 to 5 mL depending on vial strength and preferred per-dose unit count.
How many units of tirzepatide are in 2.5 mg?
It depends on the concentration. On a 10 mg vial reconstituted with 2 mL of bacteriostatic water (5 mg per mL), 2.5 mg is exactly 50 units on a U-100 syringe. With 4 mL of diluent (2.5 mg per mL), the same dose is 100 units.
Why is tirzepatide dosed weekly?
Because its half-life is roughly five days, which keeps plasma levels stable on a once-weekly schedule. That long half-life is also why a single missed dose has less effect than missing a dose of a daily peptide.
How long does a 10 mg tirzepatide vial last?
At a 2.5 mg weekly dose, a 10 mg vial supports 4 weeks of supply. The vial duration calculator runs the math for any combination of vial size, dose, and frequency.
Is tirzepatide stronger than semaglutide?
They activate different receptor combinations and are dosed at different milligram ranges, so direct milligram comparisons are misleading. The dual GIP/GLP-1 mechanism is the meaningful difference, not the raw milligram count.
Does tirzepatide need to be refrigerated?
Lyophilized powder is generally stored refrigerated, and the reconstituted vial is kept refrigerated and used within several weeks. A small insulated bag is the typical solution for keeping vials cold during travel.
Why does each new tirzepatide vial need its own log?
Because each vial may be reconstituted with a different diluent volume, producing a different concentration. Linking every dose entry to its specific vial keeps the unit count on the syringe accurate to that vial's real numbers.
How does the mechanism of tirzepatide differ from that of semaglutide?
The primary difference lies in their receptor targets. Semaglutide is a selective GLP-1 receptor agonist, meaning it is designed to activate only the GLP-1 receptor. Tirzepatide, in contrast, is a dual agonist, engineered as a single molecule that activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. Academic studies document that the addition of GIP receptor activity provides a secondary insulinotropic pathway, a feature not present in single-agonist GLP-1 peptides.
Why does the draw volume change so much when tracking a research protocol?
Protocols detailed in published studies often involve a dose titration, where the amount is systematically increased over time, for example from 2.5 mg up to 15 mg on a weekly cadence. If you reconstitute a vial to a fixed concentration, the volume needed to draw a specific dose will increase proportionally with the dose. This results in needing to calculate and draw a new, larger volume at each step of the titration schedule to obtain the correct milligram amount for that phase of the study.
What is the issue with drawing doses like 12.5 mg or 15 mg?
The challenge with higher doses is purely logistical and relates to administration volume. For a common concentration of 5 mg/mL, derived from a 10 mg vial reconstituted with 2 mL, a 12.5 mg dose requires a 2.5 mL draw, and a 15 mg dose requires a 3 mL draw. These volumes far exceed the capacity of common 1 mL insulin syringes. Therefore, researchers must plan ahead, either by using a larger syringe for administration or by reconstituting the peptide with more diluent to create a lower concentration per milliliter.

Related on Peptide Pilot

Log every Tirzepatide dose in the app

Download on the App Store
Get the App